Literature DB >> 21045599

Antiretroviral treatment 2010: progress and controversies.

Roy M Gulick1.   

Abstract

Effective antiretroviral therapy (ART) changes the clinical course of HIV infection. There are 25 antiretroviral drugs approved for the treatment of HIV infection, and current antiretroviral drug regimens are highly effective, convenient, and relatively nontoxic. ART regimens should be chosen in consideration of a patient's particular clinical situation. Successful treatment is associated with durable suppression of HIV viremia over years, and consequently, ART reduces the risk of clinical progression. In fact, current models estimate that an HIV-infected individual appropriately treated with antiretroviral drugs has a life expectancy that approaches that of the general HIV-uninfected population, although some patient groups such as injection drug users do less well. Despite these advances, continued questions about ART persist: What is the optimal time to start ART? What is the best regimen to start? When is the optimal time to change ART? What is the best regimen to change to? In addition, newer antiretroviral agents are in development, both in existing classes and in new classes such as the CD4 receptor attachment inhibitors and the maturation inhibitors. Further research will help optimize current antiretroviral treatments and strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045599      PMCID: PMC3061404          DOI: 10.1097/QAI.0b013e3181f9c09e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  43 in total

1.  Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.

Authors:  Patrice Severe; Marc Antoine Jean Juste; Alex Ambroise; Ludger Eliacin; Claudel Marchand; Sandra Apollon; Alison Edwards; Heejung Bang; Janet Nicotera; Catherine Godfrey; Roy M Gulick; Warren D Johnson; Jean William Pape; Daniel W Fitzgerald
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 2.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

3.  Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States.

Authors:  Kathleen McDavid Harrison; Ruiguang Song; Xinjian Zhang
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

4.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

5.  Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.

Authors:  Roger J Bedimo; Kathleen A McGinnis; Melinda Dunlap; Maria C Rodriguez-Barradas; Amy C Justice
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

6.  Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

Authors:  Arkaitz Imaz; Sara Villar del Saz; M Angels Ribas; Adrian Curran; Estrella Caballero; Vicenç Falcó; Manel Crespo; Inma Ocaña; Marjorie Diaz; Enrique Ruiz de Gopegui; Melcior Riera; Esteban Ribera
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

7.  Interleukin-2 therapy in patients with HIV infection.

Authors:  D Abrams; Y Lévy; M H Losso; A Babiker; G Collins; D A Cooper; J Darbyshire; S Emery; L Fox; F Gordin; H C Lane; J D Lundgren; R Mitsuyasu; J D Neaton; A Phillips; J P Routy; G Tambussi; D Wentworth
Journal:  N Engl J Med       Date:  2009-10-15       Impact factor: 91.245

8.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Authors:  Y Yazdanpanah; C Fagard; D Descamps; A M Taburet; C Colin; B Roquebert; C Katlama; G Pialoux; C Jacomet; C Piketty; D Bollens; J M Molina; G Chêne
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

9.  Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

Authors:  Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Victoria Wirtz; Max Lataillade; Judith Absalon; Donnie McGrath
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

10.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

Authors:  P Mugyenyi; A S Walker; J Hakim; P Munderi; D M Gibb; C Kityo; A Reid; H Grosskurth; J H Darbyshire; F Ssali; D Bray; E Katabira; A G Babiker; C F Gilks; H Grosskurth; P Munderi; G Kabuye; D Nsibambi; R Kasirye; E Zalwango; M Nakazibwe; B Kikaire; G Nassuna; R Massa; K Fadhiru; M Namyalo; A Zalwango; L Generous; P Khauka; N Rutikarayo; W Nakahima; A Mugisha; J Todd; J Levin; S Muyingo; A Ruberantwari; P Kaleebu; D Yirrell; N Ndembi; F Lyagoba; P Hughes; M Aber; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Whitworth; K Wangati; B Amuron; D Kajungu; J Nakiyingi; W Omony; K Fadhiru; D Nsibambi; P Khauka; P Mugyenyi; C Kityo; F Ssali; D Tumukunde; T Otim; J Kabanda; H Musana; J Akao; H Kyomugisha; A Byamukama; J Sabiiti; J Komugyena; P Wavamunno; S Mukiibi; A Drasiku; R Byaruhanga; O Labeja; P Katundu; S Tugume; P Awio; A Namazzi; G T Bakeinyaga; H Katabira; D Abaine; J Tukamushaba; W Anywar; W Ojiambo; E Angweng; S Murungi; W Haguma; S Atwiine; J Kigozi; L Namale; A Mukose; G Mulindwa; D Atwiine; A Muhwezi; E Nimwesiga; G Barungi; J Takubwa; S Murungi; D Mwebesa; G Kagina; M Mulindwa; F Ahimbisibwe; P Mwesigwa; S Akuma; C Zawedde; D Nyiraguhirwa; C Tumusiime; L Bagaya; W Namara; J Kigozi; J Karungi; R Kankunda; R Enzama; A Latif; J Hakim; V Robertson; A Reid; E Chidziva; R Bulaya-Tembo; G Musoro; F Taziwa; C Chimbetete; L Chakonza; A Mawora; C Muvirimi; G Tinago; P Svovanapasis; M Simango; O Chirema; J Machingura; S Mutsai; M Phiri; T Bafana; M Chirara; L Muchabaiwa; M Muzambi; J Mutowo; T Chivhunga; E Chigwedere; M Pascoe; C Warambwa; E Zengeza; F Mapinge; S Makota; A Jamu; N Ngorima; H Chirairo; S Chitsungo; J Chimanzi; C Maweni; R Warara; M Matongo; S Mudzingwa; M Jangano; K Moyo; L Vere; N Mdege; I Machingura; E Katabira; A Ronald; A Kambungu; F Lutwama; I Mambule; A Nanfuka; J Walusimbi; E Nabankema; R Nalumenya; T Namuli; R Kulume; I Namata; L Nyachwo; A Florence; A Kusiima; E Lubwama; R Nairuba; F Oketta; E Buluma; R Waita; H Ojiambo; F Sadik; J Wanyama; P Nabongo; J Oyugi; F Sematala; A Muganzi; C Twijukye; H Byakwaga; R Ochai; D Muhweezi; A Coutinho; B Etukoit; C Gilks; K Boocock; C Puddephatt; C Grundy; J Bohannon; D Winogron; D M Gibb; A Burke; D Bray; A Babiker; A S Walker; H Wilkes; M Rauchenberger; S Sheehan; C Spencer-Drake; K Taylor; M Spyer; A Ferrier; B Naidoo; D Dunn; R Goodall; J H Darbyshire; L Peto; R Nanfuka; C Mufuka-Kapuya; P Kaleebu; D Pillay; V Robertson; D Yirrell; S Tugume; M Chirara; P Katundu; N Ndembi; F Lyagoba; D Dunn; R Goodall; A McCormick; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Kigozi; L Muchabaiwa; M Muzambi; I Weller; A Babiker; S Bahendeka; M Bassett; A Chogo Wapakhabulo; J H Darbyshire; B Gazzard; C Gilks; H Grosskurth; J Hakim; A Latif; C Mapuchere; O Mugurungi; P Mugyenyi; C Burke; S Jones; C Newland; G Pearce; S Rahim; J Rooney; M Smith; W Snowden; J-M Steens; A Breckenridge; A McLaren; C Hill; J Matenga; A Pozniak; D Serwadda; T Peto; A Palfreeman; M Borok; E Katabira
Journal:  Lancet       Date:  2009-12-08       Impact factor: 79.321

View more
  10 in total

1.  Medication-related barriers to entering HIV care.

Authors:  Linda Beer; Jennifer L Fagan; Pamela Garland; Eduardo E Valverde; Barbara Bolden; Kathleen A Brady; Maria Courogen; Daniel Hillman; Alan Neaigus; Jeanne Bertolli
Journal:  AIDS Patient Care STDS       Date:  2012-02-09       Impact factor: 5.078

2.  Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective.

Authors:  Elizabeth Y Lambert; Jacques L Normand; Nora D Volkow
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

3.  National and international policies to mitigate disease threats.

Authors:  Christopher Dye
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-10-19       Impact factor: 6.237

Review 4.  Applying evolutionary biology to address global challenges.

Authors:  Scott P Carroll; Peter Søgaard Jørgensen; Michael T Kinnison; Carl T Bergstrom; R Ford Denison; Peter Gluckman; Thomas B Smith; Sharon Y Strauss; Bruce E Tabashnik
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

Review 5.  DNA sequencing and bar-coding using solid-state nanopores.

Authors:  Evrim Atas; Alon Singer; Amit Meller
Journal:  Electrophoresis       Date:  2012-10-30       Impact factor: 3.535

6.  Use of and Adherence to Antiretroviral Therapy in a Large U.S. Sample of HIV-infected Adults in Care, 2007-2008.

Authors:  Linda Beer; James Heffelfinger; Emma Frazier; Christine Mattson; Brad Roter; Elizabeth Barash; Susan Buskin; Todd Rime; Eduardo Valverde
Journal:  Open AIDS J       Date:  2012-09-07

Review 7.  Translational research in infectious disease: current paradigms and challenges ahead.

Authors:  Judith M Fontana; Elizabeth Alexander; Mirella Salvatore
Journal:  Transl Res       Date:  2012-01-15       Impact factor: 7.012

8.  Complications of common gynecologic surgeries among HIV-infected women in the United States.

Authors:  Ana Penman-Aguilar; Maura K Whiteman; Shanna Cox; Samuel F Posner; Susan F Meikle; Athena P Kourtis; Denise J Jamieson
Journal:  Infect Dis Obstet Gynecol       Date:  2012-05-17

Review 9.  Pharmacological inhibition of feline immunodeficiency virus (FIV).

Authors:  Hakimeh Mohammadi; Dorothee Bienzle
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

10.  Factors contributing to antiretroviral drug adherence among adults living with HIV or AIDS in a Kenyan rural community.

Authors:  Mary T Kioko; Anne M Pertet
Journal:  Afr J Prim Health Care Fam Med       Date:  2017-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.